## Boston Scientific obtains CE Mark for next generation of cardiac mapping for the FARAPULSE™ Pulsed Field Ablation System

FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with Boston Scientific mapping system to provide mapping during pulsed field ablation

LONDON, United Kingdom, 17 February, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced it has received CE mark for the navigation-enabled FARAWAVE<sup>TM</sup> NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and for the new FARAVIEW<sup>TM</sup> Software. Both technologies will integrate and expand mapping option capabilities for cardiac ablation procedures using the FARAPULSE<sup>TM</sup> Pulsed Field Ablation (PFA) System, the most clinically proven PFA system for the treatment of AF, which has already benefited 200,000 patients globally. These technologies are compatible exclusively with the company's existing cardiac mapping technology and the company's latest offering, the OPAL HDx<sup>TM</sup> Mapping System.

Today, electrophysiologists might use a separate mapping catheter before a cardiac PFA procedure to study the heart's electrical patterns and plan treatment for each patient. The FARAWAVE NAV Ablation Catheter advances on the current FARAWAVE catheter by adding magnetic navigation, allowing cardiac mapping and PFA therapy to be done with a single catheter, reducing the need for extra device changes. Mapped procedures with the FARAPULSE PFA System are shown visually for doctors using the FARAVIEW Software, which provides a dynamic view of catheter placement, shape, and rotation.

"The FARAPULSE PFA System has transformed the way we treat atrial fibrillation, and integrated mapping technology with a single catheter solution will set a new standard for clinical innovation and therapy delivery," said Caroline Bravo, vice president, Rhythm Management EMEA, Boston Scientific. "The FARAWAVE NAV Ablation Catheter and FARAVIEW Software are designed specifically for the FARAPULSE PFA System, and have the potential to increase workflow options, maintain efficiency and enhance the treatment physicians can provide to patients living with AF."

The FARAVIEW Software magnetically tracks the FARAWAVE NAV Ablation Catheter, enabling physicians to visualise where pulsed fields have been applied and observe cumulative therapy delivery to guide ablation strategy. PFA delivery with the FARAWAVE NAV Ablation Catheter can be tracked through automated FIELDTAG ™ technology, designed to assist physicians in planning, executing, and confirming therapy application by indicating the approximate pulsed field locations within the heart based on the catheter's position.

"Atrial fibrillation can significantly affect a patients' quality of life, causing symptoms such as fatigue, palpitations breathlessness," said Prof. Gábor Széplaki. "Some patients cannot manage their symptoms with medication alone. If medication is not effective, we can consider a minimally invasive technology like FARAPULSE Pulsed Field Ablation System in combination with the new FARAVIEW™ mapping software. Advanced technology like this helps to enhance our understanding of optimal treatment for atrial fibrillation. Minimally invasive technologies like FARAVIEW™ mapping enhances understanding of their atrial fibrillation to enable treatment using the FARAPULSE Pulsed Field Ablation System. "

Boston Scientific will launch the FARAWAVE NAV Ablation Catheter and the FARAVIEW Software in the EMEA region. More information is available here.

## **About Boston Scientific**

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life byproviding a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at <a href="https://www.bostonscientific.eu">www.bostonscientific.eu</a> and connect on <a href="https://www.bostonscientific.eu">LinkedIn</a> and <a href="https://www.bostonscientific.eu">X</a>, formerly Twitter.

## Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and product performance and impact, and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause

actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; manufacturing, distribution and supply chain disruptions and cost increases; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACTS: Uchenna Izundu Media Relations

+44 (0) 7772 404 018 uchenna.izundu@bsci.com

Jon Monson Investor Relations (508) 683-5450 BSXInvestorRelations@bsci.com

https://news.bostonscientific.eu/boston-scientific-obtains-ce-mark-for-next-generation-of-cardiac-mapping-for-the-farapulse-pulsed-field-ablation-system